Share

Profile & Fundamentals

Amgen Profile & Fundamentals

Name: Amgen financial chart data preview
Creator: iPulse AI
License: https://ipulseai.com/terms

Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.

Interactive annual & quarterly chartsAI financial reviewsReported source tables

Explore this pageJump to a Profile & Fundamentals section

Explore this research

Profile & Fundamentals contents

Jump directly to any section

Company and Market Context

Company Profile & Ownership

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is he

Company profile record

Amgen Inc

Common Stock · Health Care · Biotechnology

Official website

Company

Company / asset: Amgen Inc
Security type: Common Stock
Sector: Health Care
Industry: Biotechnology
HQ: 🇺🇸 United States
Head office: One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799

Leadership & scale

Chief executive: Mr. Robert A. Bradway
CEO year born: 1963
Full-time employees: 31.5K
Fiscal year end: December
IPO date: 1983-06-17

Fundamentals snapshot

Updated 2026-09-14

Market Cap: USD 209.8B
P/E: 24.0x
Revenue (Q2 26): USD 10.1B
Profit (Q2 26): USD 2.4B
Dividend Yield: 1.8%
Revenue (FY 25): USD 36.7B
Shares in public float: 539.2M
Insider ownership: 0.23%

Reporting & identifiers

Symbol: AMGN.NASDAQ
Listing: 🇺🇸 United States | Dividend Tax: 30%
Ticker Currency: USD
Income Statement Currency: USD
Balance Sheet Currency: USD
Cash Flow Currency: USD
EPS Currency: USD
Contract Type: SPOT
ISIN: US0311621009
Asset ID: equity_3f8ad8b5-f4b0-5cb9-9c03-b91a45b1c70a

Ownership

Shares Outstanding

Shares outstanding

Annual reported shares outstanding. Values in shares.

Top holders

BlackRock Inc47,100,472 shares · 8.71% · Reported 2026-03-31
Vanguard Capital Management, LLC35,014,232 shares · 6.48% · Reported 2026-03-31
State Street Corp30,548,488 shares · 5.65% · Reported 2026-03-31
Capital World Investors29,075,329 shares · 5.38% · Reported 2026-06-30
Vanguard MStar Total Stk Mkt Idx Invest17,186,059 shares · 3.18% · Reported 2026-07-31
Amvescap Plc.15,885,506 shares · 2.94% · Reported 2026-03-31
Morgan Stanley - Brokerage Accounts15,836,058 shares · 2.93% · Reported 2026-03-31

View more holders (8)

Geode Capital Management, LLC15,430,524 shares · 2.85% · Reported 2026-03-31
Vanguard Portfolio Management, LLC14,621,148 shares · 2.70% · Reported 2026-03-31
Vanguard 500 Index Investor14,169,752 shares · 2.62% · Reported 2026-07-31
Charles Schwab Investment Management Inc12,773,386 shares · 2.36% · Reported 2026-03-31
Schwab US Dividend Equity ETF™12,257,690 shares · 2.27% · Reported 2026-08-29
Invesco QQQ Trust11,610,350 shares · 2.15% · Reported 2026-08-31
American Funds Income Fd of Amer A7,758,812 shares · 1.44% · Reported 2026-06-30
JPMorgan Chase & Co7,277,837 shares · 1.35% · Reported 2026-03-31

Earnings, Profitability & Valuation

Earnings & Revenue

AI Review

The company is showing strong top-line revenue growth, driven by its newly acquired rare-disease treatments and established cardiovascular drugs. However, actual net income and free cash flow have faced some pressure due to the high costs of integrating these new businesses and paying off debt. Analysts agree that the company's ability to generate cash remains highly resilient, providing a safe cushion during economic uncertainty. However, there is a clear disagreement about the future path: some believe that upcoming patent expirations on older, high-margin drugs will cause a temporary drop in earnings, while others argue that the rapid scaling of new treatments will easily bridge the gap. Overall, the company's financial engine is strong, but its future growth depends heavily on the successful launch of its new pipeline.

Revenue, Net Income, and Free Cash Flow

Revenue
Free cash flow
Net income

Annual reported financial results, converted using the statement's recorded USD conversion. Missing values are omitted. Values in USD.

Valuation

Historical P/E Ratio

Published P/E

Published valuation snapshots. Trailing four-quarter earnings where available; annual earnings otherwise. Non-positive earnings are omitted. Values in times earnings.

Profitability & Margins

AI Review

The company maintains exceptionally high gross margins, reflecting the strong pricing power of its specialized biologic drugs. However, operating and net margins have been squeezed recently by high research costs and acquisition-related expenses. Analysts agree that margins will face continued pressure as older, highly profitable blockbusters lose patent protection and face cheap generic competition. The main point of disagreement is how quickly margins will recover. Optimists believe that the high-margin rare-disease portfolio and automated manufacturing will quickly restore profitability, while cautious observers warn that launching a mass-market weight-loss drug will require massive marketing spend that will keep margins depressed for longer.

Profitability Margins

Gross margin
Operating margin
Net margin
Free cash flow margin

Annual gross, operating, net income and free cash flow divided by revenue for matching reporting dates. Values in percent.

Complete Research Workspace

Unlock the complete Profile & Fundamentals

Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.

Sign in to check access View Base plan

Paywalled preview begins: Reported Data Tables — chart preview

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Reported Data Tables — chart preview

The following tables contain the same values as the financial charts above. Monetary values are USD; margins are percentages. Missing inputs are not estimated. Use is subject to the iPulse AI Terms of Service and applicable source rights.

Source: eodhd. Statement snapshots with chart transformations and ratios calculated by iPulse AI. Snapshot retrieved 2026-09-15.

Annual earnings and profitability
Period end	Revenue	Free cash flow	Net income	Gross margin	Operating margin	Net margin	Free cash flow margin
2016-12-31	22,991,000,000	9,517,000,000	7,722,000,000	81.9	42.6	33.59	41.39
2017-12-31	22,849,000,000	10,513,000,000	1,979,000,000	82.19	43.65	8.66	46.01
2018-12-31	23,747,000,000	10,558,000,000	8,394,000,000	82.73	43.22	35.35	44.46
2019-12-31	23,362,000,000	8,532,000,000	7,842,000,000	81.35	41.41	33.57	36.52
2020-12-31	25,424,000,000	9,889,000,000	7,264,000,000	75.77	35.95	28.57	38.9
2021-12-31	25,979,000,000	8,381,000,000	5,893,000,000	75.16	29.4	22.68	32.26
2022-12-31	26,323,000,000	8,785,000,000	6,552,000,000	75.66	36.34	24.89	33.37
2023-12-31	28,190,000,000	7,359,000,000	6,717,000,000	70.02	28.01	23.83	26.11
2024-12-31	33,424,000,000	10,394,000,000	4,090,000,000	61.53	21.71	12.24	31.1
2025-12-31	36,741,000,000	8,100,000,000	7,711,000,000	70.8	29.06	20.99	22.05

Published valuation snapshots
Period end	P/E (times earnings)	Earnings basis
2025-12-31	23.05	Trailing four quarters
2024-12-31	34.54	Trailing four quarters
2023-12-31	23.15	Trailing four quarters
2022-12-31	21.61	Annual net income
2021-12-31	21.57	Annual net income

Shares outstanding — chart values
Reporting date	Shares outstanding
2017-01-01	724,000,000
2018-01-01	640,000,000
2019-01-01	598,000,000
2020-01-01	585,000,000
2021-01-01	565,000,000
2022-01-01	539,000,000
2023-01-01	540,000,000
2024-01-01	542,000,000
2025-01-01	543,000,000
2026-01-01	544,000,000

End of the paywalled preview

The excerpt from Reported Data Tables — chart preview to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Earnings, Profitability & Valuation
- Complete profitability ratios
- EPS history and estimate comparisons
- Execution vs expectations
- Annual and quarterly financial views
Capital Expenditure & R&D
- Capital allocation AI review
- Annual capital expenditure
- Investment intensity trends
- Capex and R&D intensity indicators
Balance Sheet
- Balance sheet AI review
- Assets, debt and equity
- Capital structure
- Liquidity and leverage
- Retained earnings
Dividends & Actions
- Cash dividends paid
- Dividend indicators
- Buybacks and issuance
- Combined shareholder returns
- Available corporate actions
Company Events
- Dated insider transactions
- Material company activity

Explore complete public research examples

These public assets show the complete asset profiles, fundamental datasets and analysis. Their findings concern those assets, not this report.